中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

HCV基因分型、AFP-L3与P53抗体联合检测在HCV相关肝细胞癌中的诊断价值

杨自力 张任飞 何欣 张洁 万祎

欧强, 徐燕华, 曲立娟, 黄玲. 强肝胶囊对非酒精性脂肪性肝病患者胰岛素抵抗指数和肝纤维化评分的影响[J]. 临床肝胆病杂志, 2016, 32(10): 1951-1954. DOI: 10.3969/j.issn.1001-5256.2016.10.027.
引用本文: 欧强, 徐燕华, 曲立娟, 黄玲. 强肝胶囊对非酒精性脂肪性肝病患者胰岛素抵抗指数和肝纤维化评分的影响[J]. 临床肝胆病杂志, 2016, 32(10): 1951-1954. DOI: 10.3969/j.issn.1001-5256.2016.10.027.
Ou Qiang, Xu YanHua, Qu LiJuan, Huang Ling. Effect of Qianggan capsules on insulin resistance index and liver fibrosis score in patients with nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2016, 32(10): 1951-1954. DOI: 10.3969/j.issn.1001-5256.2016.10.027.
Citation: Ou Qiang, Xu YanHua, Qu LiJuan, Huang Ling. Effect of Qianggan capsules on insulin resistance index and liver fibrosis score in patients with nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2016, 32(10): 1951-1954. DOI: 10.3969/j.issn.1001-5256.2016.10.027.

HCV基因分型、AFP-L3与P53抗体联合检测在HCV相关肝细胞癌中的诊断价值

DOI: 10.3969/j.issn.1001-5256.2020.10.013
基金项目: 

四川省卫生和计划生育委员会科研课题(18PJ111); 

详细信息
  • 中图分类号: R735.7

Value of combined determination of hepatitis C virus genotype,AFP-L3,and P53 antibody in the diagnosis of hepatitis C virus-related hepatocellular carcinoma

Research funding: 

 

  • 摘要: 目的探讨HCV基因分型、甲胎蛋白异质体(AFP-L3)和P53抗体联合检测在HCV相关肝细胞癌(HCV-HCC)中的诊断价值。方法选取2016年1月-2019年12月在绵阳市第三人民医院确诊的HCV-HCC患者84例及良性肝病对照组(丙型肝炎患者、HCV肝硬化患者) 84例。分别采用PCR-反向点杂交技术、ELISA方法、电化学发光法检测HCV基因分型、P53抗体、AFP-L3。计量资料组间比较采用t检验和Kruskal-Wallis H检验;计数资料组间比较采用χ2检验。通过logistic回归分析和受试者工作特征曲线(ROC曲线)比较各指标对HCV-HCC的诊断价值。结果 HCV-HCC组HCV 1b基因型(%)、AFP-L3(%)、P53抗体明显高于良性肝病对照组(χ2=5.714、Z=-9.27、Z=-9.92,P值均<0.05)。logistic回归分析结果显示,HCV基因分型、AFP-L3(%)、P53抗体对HCV-HCC的影响均有统计学意义(P值均<0.05)。将上述单项指标重新拟合并建立模型:Logit(Y)=-3...

     

  • [1] MOROZOV VA,LAGAYE S. Hepatitis C virus:Morphogenesis,infection and therapy[J]. World J Hepatol,2018,10(2):186-212.
    [2] WHO. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection[M]. Geneva:Word Health Organization,2018.
    [3] Expert Panel of Antiviral Therapy for Hepatocellular Carcinoma.Expert consensus on antiviral therapy to hepatitis B/C virusrelated hepatocellular carcinoma[J]. J Clin Hepatol,2014,30(5):390-395.(in Chinese)肝细胞癌抗病毒治疗专家组.HBV/HCV相关性肝细胞癌抗病毒治疗专家共识[J].临床肝胆病杂志,2014,30(5):390-395.
    [4] LI B,LI BA. The significance of autoantibodies detection for the diagnosis of primary hepatic carcinoma[J]. Chin J Lab Med,2016,39(2):76-78.(in Chinese)李波,李伯安.自身抗体检测在原发性肝癌诊断中的意义[J].中华检验医学杂志,2016,39(2):76-78.
    [5] Bureau of Medical Administration,National Health Commission of the People’s Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China(2019 edition)[J]. J Clin Hepatol,2020,36(2):277-292.(in Chinese)中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)[J].临床肝胆病杂志,2020,36(2):277-292.
    [6] XIE F,YU YC,XUE Z,et al. Screening strategy for primary hepatocellular carcinoma based on different combinations of protein induced by vitamin K absence or antagonist-II,alpha-fetoprotein,and alpha-fetoprotein-L3[J]. J Clin Hepatol,2019,35(9):1975-1979.(in Chinese)谢芳,于乐成,薛珠,等.基于PIVKA-Ⅱ、AFP和AFP-L3不同组合模式的肝细胞癌筛查策略探讨[J].临床肝胆病杂志,2019,35(9):1975-1979.
    [7] GUAN GW,YAO MJ,QIAN XJ,et al. Value of combined measurement of alpha-fetoprotein and alpha-fetoprotein L3%in the diagnosis of hepatocellular carcinoma[J]. J Clin Hepatol,2019,35(7):1514-1519.(in Chinese)关贵文,姚明解,钱相君,等.AFP和AFP-L3%联合检测在肝细胞癌诊断中的应用价值[J].临床肝胆病杂志,2019,35(7):1514-1519.
    [8] CAO YL,SHAN J,GONG ZZ,et al. Interpretation of the TRIPOD statement:A reporting guideline for multivariable prediction model for individual prognosis or diagnosis[J]. Chin J Evid-based Med,2020,20(4):492-496.(in Chinese)曹煜隆,单娇,龚志忠,等.个体预后与诊断预测模型研究报告规范———TRIPOD声明解读[J].中国循证医学杂志,2020,20(4):492-496.
    [9] National Health and Family Planning Commission of The People’s Republic of China. WS 213-2018 Diagnosis for hepatitis C[J]. J Clin Hepatol,2018,34(8):1619-1621.(in Chinese)中华人民共和国国家卫生和计划生育委员会.WS 213—2018丙型肝炎诊断[J].临床肝胆病杂志,2018,34(8):1619-1621.
    [10] Bureau of Medical Administration,National Health and Family Planning Comission of the People’s Republic of China. Diagnosis,management,and treatment of hepatocellular carcinoma(V2017)[J]. J Clin Hepatol,2017,33(8):1419-1431.(in Chinese)中华人民共和国卫生和计划生育委员会医政医管局.原发性肝癌诊疗规范(2017年版)[J].临床肝胆病杂志,2017,33(8):1419-1431.
    [11] OBUCHOWSKI NA,MCCLISH DK. Sample size determination for diagnostic accuracy studies involving binormal ROC curve indices[J]. Stat Med,1997,16(13):1529-1542.
    [12] ZHOU M,WANG H,ZENG X,et al. Mortality,morbidity,and risk factors in China and its provinces,1990-2017:A systematic analysis for the Global Burden of Disease Study 2017[J].Lancet,2019,394(10204):1145-1158.
    [13] KOZIOL JA,IMAI H,DAI L,et al. Early detection of hepatocellular carcinoma using autoantibody profiles from a panel of tumor-associated antigens[J]. Cancer Immunol Immunother,2018,67(5):835-841.
    [14] LEE MH,YANG HI,LU SN,et al. Hepatitis C virus genotype1b increases cumulative lifetime risk of hepatocellular carcinoma[J]. Int J Cancer,2014,135(5):1119-1126.
    [15] BUSATO D,MOSSENTA M,BABOCI L,et al. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment[J]. Expert Rev Clin Pharmacol,2019,12(5):453-470.
    [16] HWANG HM,HEO CK,LEE HJ,et al. Identification of antiSF3B1 autoantibody as a diagnostic marker in patients with hepatocellular carcinoma[J]. J Transl Med,2018,16(1):177.
    [17] MA H,SUN X,CHEN L,et al. Multiplex immunochips for highaccuracy detection of AFP-L3%based on surface-enhanced raman scattering:Implications for early liver cancer diagnosis[J]. Anal Chem,2017,89(17):8877-8883.
    [18] YU R,TAN Z,XIANG X,et al. Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on realworld clinical data[J]. BMC Cancer,2017,17(1):608.
  • 期刊类型引用(16)

    1. 巴明玉,潘研,王娴,陈亚琳,燕树勋. 强肝胶囊对非酒精性脂肪肝肥胖患者糖脂代谢水平及肝功能的影响. 中医学报. 2024(02): 416-420 . 百度学术
    2. 范文,郑垂仰,周旋,孔怡琳,潘丰满,杨钦河,张玉佩. 6种中成药治疗非酒精性脂肪性肝病有效性和安全性的网状Meta分析. 中药新药与临床药理. 2023(11): 1612-1622 . 百度学术
    3. 崔姗姗,刘英,江霞. 非酒精性脂肪性肝病与胰岛素抵抗的研究进展. 医学信息. 2022(10): 66-69 . 百度学术
    4. 舒祥兵,操颖,顾晔,杨志新,季光,张莉. 强肝胶囊促进肝糖原合成降低大鼠高血糖的机制研究. 上海中医药大学学报. 2021(03): 45-51 . 百度学术
    5. 贾英杰,张晓博,张新元,杨红霞,郭争荣. 强肝胶囊对猪血清诱导大鼠肝纤维化的治疗作用. 河北医药. 2021(20): 3104-3107 . 百度学术
    6. 朱丹,孙婷婷,陈兰羽,谢铮. 脂肪性肝病中医药认识. 辽宁中医药大学学报. 2020(05): 70-73 . 百度学术
    7. 崔翔,刘玲兰,华鹏,郭薇,薛敬东. 从脾论治非酒精性脂肪性肝病的体会与研究概况. 中医临床研究. 2020(14): 136-138 . 百度学术
    8. 郭明升,刘娟,郭英杰,籍芳华,郝艳爽. 阿托伐他汀联用脂康颗粒或强肝胶囊用于脑梗死二级预防效果比较. 现代中西医结合杂志. 2020(22): 2400-2404+2446 . 百度学术
    9. 王秀琴. 强肝胶囊联合甘草酸二铵肠溶胶囊治疗非酒精性脂肪肝的效果. 河南医学研究. 2019(06): 1089-1091 . 百度学术
    10. 黄静,陈湘清,郭东升,吴奋. 同步抗感染治疗对合并幽门螺杆菌感染非酒精性脂肪肝病患者治疗结局的影响研究. 重庆医学. 2018(01): 97-100 . 百度学术
    11. 陈少颖,易新宇,周小博,张荣臻. 中医药治疗非酒精性脂肪肝的研究进展. 大众科技. 2018(06): 68-70 . 百度学术
    12. 周桃梅,杨上文,汪剑波. 强肝胶囊联合二甲双胍治疗非酒精性脂肪肝的疗效及其对Nod样受体-3炎症小体的影响. 中国医院统计. 2018(03): 206-208 . 百度学术
    13. 柳琳琳,毛德文,吕建林,黄瑞. 强肝胶囊对非酒精性脂肪性肝病患者疗效及安全性的Meta分析. 中成药. 2018(08): 1715-1720 . 百度学术
    14. 李滨,张佳圆,王凤永,李春晖,齐丽韫,王玉华,赵培利. 胆宁片治疗非酒精性脂肪肝临床效果及对血脂、肝功能和肝纤维化的影响. 解放军医药杂志. 2018(10): 93-96 . 百度学术
    15. 朱紫馨,祝丽丽,程明亮. 同步抗感染治疗非酒精性脂肪肝合并幽门螺杆菌感染的效果观察. 临床合理用药杂志. 2018(31): 58-59 . 百度学术
    16. 李军祥,王允亮,郭一,谢添弘. 中医药治疗非酒精性脂肪性肝病专题笔谈. 中国中西医结合消化杂志. 2017(11): 801-804 . 百度学术

    其他类型引用(13)

  • 加载中
计量
  • 文章访问数:  1143
  • HTML全文浏览量:  35
  • PDF下载量:  116
  • 被引次数: 29
出版历程
  • 收稿日期:  2020-05-19
  • 出版日期:  2020-10-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回